SNY Jan 2024 43.000 call
| Previous close | 13.90 |
| Open | 13.90 |
| Bid | 10.10 |
| Ask | 14.50 |
| Strike | 43.00 |
| Expiry date | 2024-01-19 |
| Day's range | 13.90 - 13.90 |
| Contract range | N/A |
| Volume | |
| Open interest | 58 |
- Investing.com
Sanofi Anticipates Significant Hit to Q3 Earnings and Sales Due to Currency Fluctuations
French pharmaceutical giant, Sanofi (NASDAQ:SNY), has forecasted a substantial impact on its third-quarter sales and business earnings per share (EPS) due to currency movements. This prediction is based on foreign exchange fluctuations observed until September 15, as per the company's preliminary estimates released last Friday.
GlobeNewswirePress Release: Availability of the Q3 2023 Memorandum for modelling purposes
Availability of the Q3 2023 Memorandum for modelling purposes Paris, France – September 22, 2023. Sanofi announced today that its Q3 2023 Memorandum for modelling purposes is available on the "Investors" page of the company's website: https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/q3-results-2023 As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various
Yahoo FinanceSanofi CEO: How AI may ease the pressure of Medicare price negotiations
Sanofi is all in on AI and thinks it could help alleviate patent timeline pressures from the Inflation Reduction Act.
